The results suggest that the combination of lapatinib plus capecitabine can improve progression-free survival and overall survival in patients with HER2-positive breast cancer that cannot be controlled by trastuzumab (Madden et al., 2017). The gene discussed is ERBB2; the disease is breast cancer.